Your search for baricitinib returned 6 results

Methods to prevent and treat COVID-19 in cancer patients have had to evolve alongside the SARS-CoV-2 virus.

The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.

The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.

Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.

Findings showed that the trial did not meet statistical significance on the primary endpoint.

Both doses of baricitinib met the primary end point, demonstrating statistically significant improvement in scalp hair regrowth compared with placebo.